​​​The annual EPM Global Job Confidence Index aims to measure the beating heartbeat of the life sciences labor market, their confidence in the economy, securing or finding a job, compensation and bonus, flexible working patterns, and whether the bull-bear factors in employment have altered.

​As many businesses are finally reopening their doors, the life sciences workplace will be virtually unrecognizable. What short and long-term impact will the pandemic have on the workplace? How will these changes affect talent? While the global pandemic will inevitably result in long term transformations to the form and function of the workspace, the short term will mostly b...

​Workforce flexibility, employee wellbeing, and the rise of technology dominated talent topics last year and continues to be a focal point for 2021. There is a discussion concerning talent mobility that, in many ways, may have been swept under the carpet on the back of the global pandemic. This raises the question, has the pandemic halted the movement of talent through the l...

​It’s tempting to enter 2021 with blind optimism, eager to put the challenges of 2020 behind us. However, to learn as much as possible from the adversities we all faced last year, we’d like to suggest that we begin 2021 with a brief period of reflection.

​Phaidon International, the parent brand of EPM Scientific, is honoured to be recognised for its part in BioNTech's journey towards a successful vaccine against Covid-19.​The German-based biotechnology company who was the first to bring a successful vaccine against Covid-19 to market, acknowledges key partners in making this historic achievement possible.Ugur Sahin, CEO and ...

​We are at a crossroads. The health and wellbeing of the workforce has never been more closely intertwined with the state of the economy.The public health crisis caused by Covid-19 has forced operational change and reflection on the way that people organize and work. Global lockdowns have meant that many companies have shifted to remote working – where they are able to – res...

In this complex social and economic climate, it can be hard to understand how current and prospective employees are feeling and thinking. Thanks to our expansive network, we are able to gauge the sentiment and aspirations of the life sciences workforce in Europe, and share that vital information with you. The EPM Scientific Job Confidence Index 2020 is a new annual report th...

​​The race is on for a gender equal workforce throughout the life sciences sector. In Germany, one third of scientists and engineers are women (33%), significantly behind the European Union average of 40%. How can we address the imbalance?  Bethan Williams, SVP - Head of Commercial at EPM Scientific, discusses the unique position that recruiters play in furthering gender equ...

​Should more biotech and pharma companies use artificial intelligence ​to increase the diversity of their candidate pools? Only 9.9% of the STEM workforce are women of color, according to the National Science Foundation. As we explored in the first part of this series, women of color are uniquely disadvantaged when seeking employment. From recruiters and hiring mangers, too ...

​90% of CEOs report that diversity is a top business priority, yet the dial towards progress has hardly moved in recent years. A quantitative study by MassBio showed that although women make up half of the entry-level positions in biotech, they fill only 20 percent of senior leadership slots and 10 percent of board seats. While a 2017 study of the US biotech industry by Natu...

​Globalization and digitization have changed the world’s economy, and now they are changing health. The biotech and pharma markets make and sell the therapies we use to rejuvenate and repair our bodies. As our technology changes, so does our health, and the potential for human health has never been greater.   So how do we communicate novel therapeutics to life sciences profe...

​We are delighted to announce Andrew McNeilis, Chief Commercial Officer, will be moderating a panel this year at Boston BD, taking place on September 10th, 2019. This forum convenes C-level executives to discuss the most pressing business development challenges and opportunities facing the biopharma industry. This conference is a part of Biotech Week Boston, a festival of in...

​​For many emerging US-based biotech companies, taking their first product to Europe is a daunting prospect. Directly launching abroad is a difficult path, with many companies deciding to out-license rights for that territory instead. While doing so cuts down risk, it typically reduces profits and inhibits the potential to create a global brand and market strategy; companies...

​Biotech start-ups can be nimble and responsive if they utilize a small, tight-knit, interdisciplinary team. However, the minute work-groups start to expand they are susceptible to the founder’s dilemma. So how can an elite team find the right recruits that will align in terms of their technical skills, experience and vision, as well as their cultural fit? Small teams can be...

​In the last decade, innovations in cell and gene-based therapies have changed the Oncology recruitment market. So what does a top Oncology candidate look like in 2019?In the lead-up to the American Society of Clinical Oncology (ASCO) annual conference, we always take stock of current trends in Oncology recruitment. In 2019 new therapies, like gene editing, are driving the m...

​Up to 77% of biotech and pharma outsource portions of their analytics or production. There are many reasons to outsource, in source, or stay completely in-house. For biometrics teams, outsourcing can increase standardization while staying in-house decreases turnaround time.Biotech and pharma often debate whether to outsource analytics. Benefits of outsourcing can include re...

​​In the past, biotech startups have sought to partner with big pharmaceutical companies.  However, the market is changing — in 2019 it may be better to license directly in Europe.For a US-based pharmaceutical company, the prospect of taking a new drug to market in Europe can be daunting.  Many young biotech companies decide to out-license for royalty or milestone payments i...

​UCSFs bioartificial kidney is an exciting breakthrough which circumvents the need for tissue-blood supply, using  cyborg-like silicon chips. In this article we explore UCSF’s Kidney Project, the latest applications of tissue engineering, and the recruitment trends within the pharma and biotech fields.We have previously discussed how the fields of tissue-engineering and rege...

​Tissue-engineered substrates like Axogen nerve-grafts and 3D-printed hydrogels have penetrated past the hype phase of the Garner hype cycle to the main market.  Tissue-engineering and regenerative medicine are hot topics lately.  While the average person associates these therapies with idealistic sci-fi, the truth is that these therapies have exited controversial trial-and-...

​​In September 2018 the National Health Service England approved Novartis’ game-changing CAR-T therapy KYMRIAH® (tisagenlecleucel) for the treatment of childhood acute lymphoblastic leukaemia (ALL). So far, CAR-T had only been available to patients in Europe via clinical trials.As documented by Pharma Times this treatment is approved for “patients up to 25 years old with B c...